The Methodist Hospital Research Institute
Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies.
Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, random…
Inclusion Criteria (IPT Cohort): * Adult males (biological sex at birth), aged 22 to 80 years. * History of prostate treatment (e.g., radical prostatectomy, TURP, HoLEP, Aquablation, water vapor therapy, photoselective vaporization) ≥ 6 months prior. * Answers "yes" to any sub-item of Question 6 on the ICIQ-UI SF ("When does urine leak?", such as leaks before reaching the toilet, cough/sneeze, during sleep, physical activity, post-void dribbling, or no obvious reason). * Montreal Cognitive Assessment (MoCA) score \> 10. * Eligible per MRI safety screening questionnaire. Inclusion Criteria (C…
The Magstim Rapid2 system is a magnetic stimulation system capable of selectively inducing, modulating, or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS. Utilizing the StimGuide navigation system, the investigators will accurately target the pelvic supplementary motor area (pSMA). The Magstim Rapid2 system is used in this study to deliver either high-frequency (excitatory) or low-frequency (inhibitory) rTMS to assess physiological and neurofunctional effects on continence control in men with incontinence after prostate treatment (IPT).
Non-interventional control consistent of questionnaires and baseline brain functional MRI (fMRI) with no rTMS stimulation.